Adoptive T Cell Therapy:
|
|
- Buddy Walters
- 5 years ago
- Views:
Transcription
1 Adoptive T Cell Therapy: A Paradigm for Combination Strategies Cassian Yee MD Professor Melanoma Medical Oncology Immunology Director Solid Tumor Cell Therapy cyee@mdanderson.org skype name: tcelltherapy
2 Adoptive T Cell Therapy: Green Eggs and Ham Cassian Yee MD Professor Melanoma Medical Oncology Immunology Director Solid Tumor Cell Therapy cyee@mdanderson.org skype name: tcelltherapy
3 Immunotherapy Green Eggs and Ham
4 Adoptive T Cell Therapy Immune Checkpoint Blockade
5 Adoptive T Cell Therapy: Beer-Margarita Paradigm Cassian Yee MD Professor Melanoma Medical Oncology Immunology Director Solid Tumor Cell Therapy cyee@mdanderson.org skype name: tcelltherapy
6 Two great tastes that taste great together! The Beer Beer Margarita paradigm The Margarita
7
8 How to make a beer? TIL Tumor-infiltrating Lymphocytes TIL enrichment IL-2 TCR/CAR Engineered T cells Chimeric TCR + zeta Chimeric Ig + zeta Receptor Transfer ETC Endogenous T cell Therapy Cloning Cell sorting Antigen-specific T Cell Enrichment
9 TIL Tumor-infiltrating Lymphocytes TCR/CAR Engineered T cells No knowledge of tumor antigen required Effective for melanoma Potentially other TIL+ tumors Effector cell enrichment Serious toxicities, Selection bias Potential off-the-shelf Genetic enhancement possible Leukemia Potentially other malignancies Serious toxicities Regulatory/ Safety
10 Endogenous T Cell Therapy (ETC) Source Peripheral Blood < % TCR repertoire self-selected affinity Unbiased from TIL Accessible Peripheral blood Low morbidity/outpatient Regulatory simplicity Genetic modification Rapid deployment Discovery Implementation Flexibility Time and labor-intensive technically challenging
11 Endogenous T Cell therapy ETC Source Enrichment Expansion Peripheral Blood APC + peptide STIM 1 < % > 80 % > 80 %
12 CD8+ T cell clones HD Cytoxan LD IL-2 CD8+ T cell TCR
13 Lymphodepletion building a better environment CD8+ T cell clones HD Cytoxan LD IL-2 PNAS 2012
14 Efficacy
15 Efficacy
16 Efficacy Patient Target Toxicity Disease Sites Response Tyrosinase F,N,R Cervical,supraclavicular LN, Chest Wall, Breast Pulmonary nodules Tyrosinase F Mediastinal, Pulmonary nodules PD MR MART-1 F,N,R Mesenteric LN, scapular subcutaneous dz MART-1 F, N, R Pulmonary, inguinal, subcutaneous MART-1 F, N,R Right and left kidneys, adrenal, liver MART-1 F, N, R Mediastinal, supra clavicular, mammary chain, periportal, portacaval nodes. CR (> 12 mths) PR- PR- PNAS 2012
17 CTL frequency/10^6 Persistence Complete Response Effector Memory % 5.3% Central Memory 1.1% CD45 RO+ CD28++ CD127-hi 0 D Days post Infusion Progressive Disease Effector Memory CD45 RO+ CD28- CD127-lo Days post Infusion
18 All T cells are equal, but some are more equal than others Apologies to G. Orwell 18
19 A more equal T cell CD8+ T cell TCR CD127 CD28
20 Can we prospectively isolate central memory CD8 T cells? Naïve Central Memory Effector Memory Terminal Effector cytolytic proliferative CD28+ CD127+ CD45RA+ CD28++ CD127+ CD45RO+ CD28 - CD127- CD45RO+ CD28 - CD127- CD45RA+
21 Cytokine Modulation Enriches for Central Memory T cells Peripheral Blood Stim # 1 APC + peptide Frequency Surface Phenotype Functional Assays Affinity γ- chain receptor cytokines IL-2 IL-7 IL-15 IL-21 J Immunol 2005 Blood 2008 Science Transl Med 2013
22 Interleukin-2 (pg/ml) % of Max FL2-H: PE-M26-tet FL2-H: PE-M26-tet 10 4 IL-2, -7 or IL FL1-H: FITC FL1-H: FITC FL4-H: APC-CD28 CD T2 unpulsed T2 + M27pept T2 + M27pept +CTLA4-Ig Longer-Lasting (IL-2 producing, helperindependent CTL) IL-2, -7, -15 IL-21 treated 2005 J Immunol 2008 Blood 2013 Sci Trans Med
23 CD8+ T cell TCR CD127 CD28 Naïve Central Memory Effector Memory Terminal Effector cytolytic proliferative CD28+ CD127+ CD45RA+ CD28++ CD127+ CD45RO+ CD28 - CD127- CD45RO+ CD28 - CD127- CD45RA+
24 Priming with IL-21 Generates Central Memory-type T cell IL-2 CD8+ T cell TNF-a TCR IFN-g CD28++ CD127+ CD45RO+ CD127 CD28 helper-independent CTL (Tcm) J Immunol 2005 Blood 2008 Science Transl Med 2013
25 IL-2 TNF-a Intrinsic (beer) CD127 CD8+ T cell IFN-g TCR CD28 Extrinsic (margarita) Pre- Chemotherapy XRT Select Post- Cytokine help - Low-dose IL-2 - High-dose IL-2 Other g-chain receptor cytokines Anti-CTLA4, Anti PD-1 Agonist antibodies Vaccine + adoptive therapy Oncolytic virotehrapy
26 Blockade of Immune Checkpoint Inhibitor CTLA4
27 Blockade of Immune Checkpoint Inhibitor CTLA4 Transferred tumor antigen-specific T cells enhanced proliferative potential Endogenous tumor antigen-specific T cells lower threshold for activation Leads to antigen-spreading Multivalent response Eradicate / Modulate function CTLA4+ Tregs
28 Phase I/II Trial of Adoptive T Cell Therapy in Combination with Immune Checkpoint Blockade IL-2 TNF-a CD127 CD8+ T cell IFN-g TCR CD28 Metastatic Melanoma HLA-A2+ MART cells/m 2 Aude Chapuis IL-21-CD8+ T cells Anti-CTLA4 (D1) Anti-CTLA4 (D22/W3) Anti-CTLA4 (D43/W6) Anti-CTLA4 (D64/W9) LD IL-2 Chapuis, Greenberg
29 Clinical Responses In Patients with Metastatic Melaonma Receiving Adoptive T Cell Therapy And Concurrent Anti-CTLA4 Patient Prior Ipilimumab treatment failure 1 YES 2 YES 3 NO 4 YES 5 NO 6 NO 7 NO 8 NO 9 NO 10 NO
30 Clinical Responses In Patients with Metastatic Melaonma Receiving Adoptive T Cell Therapy And Concurrent Anti-CTLA4 Patient Prior Ipilimumab treatment failure 1 YES 2 YES 3 NO 4 YES 5 NO 6 NO 7 NO 8 NO 9 NO 6 weeks (-2) (-2) (0) PD (69) PD (+30) PD (+31) (-45) (+8) (-41) 12 weeks (-34) (-6) (+19) (+17) PR (-90) (+21) 16/19 weeks (-7) PD (+27) PR (-71) 28 weeks PR (-80) PD (+25) CR (-100) 40 weeks PR (-90) 84 weeks CR (-100) 10 NO PR (-76) PR (-79)
31 Clinical Responses In Patients Receiving Adoptive T Cell Therapy And Concurrent Anti-CTLA4 Patient Prior Ipilimumab treatment failure 1 YES 2 YES 3 NO 4 YES 5 NO 6 NO 7 NO 8 NO 9 NO 6 weeks (-2) (-2) (0) PD (69) PD (+30) PD (+31) (-45) (+8) (-41) 12 weeks (-34) (-6) (+19) (+17) PR (-90) (+21) 16/19 weeks (-7) PD (+27) PR (-71) 28 weeks PR (-80) PD (+25) CR (-100) 40 weeks PR (-90) 84 weeks CR (-100) 10 NO PR (-76) PR (-79) WHO RECIST Criteria
32 Clinical Responses In Patients Receiving Adoptive T Cell Therapy And Concurrent Anti-CTLA4 Patient Prior Ipilimumab treatment failure 1 YES 2 YES 3 NO 4 YES 5 NO 6 NO 7 NO 8 NO 9 NO 6 weeks (-2) (-2) (0) PD (69) PD (+30) PD (+31) (-45) (+8) (-41) 12 weeks (-34) (-6) (+19) (+17) PR (-90) (+21) 16/19 weeks (-7) PD (+27) PR (-71) 28 weeks PR (-80) PD (+25) CR (-100) 40 weeks PR (-90) 84 weeks CR (-100) 10 NO PR (-76) PR (-79) Immune-related Response Criteria
33 Clinical Response Adoptive CTL therapy + anti-ctla4
34
35 35
36 Persistence
37 Acquisition of Central Memory Markers Correlates with Clinical Response
38
39 Spots/100,000 PBMC Antigen-spreading PATIENT #1 50% clinical response at 24 weeks 25 Mart MART NY-ESO gp Tyrosinase 8 Mage A3 INF D+189 INF D+83 INF D+43 INF D-6 INF #2 D+50 INF #2 D+29 INF #2 D+0 INF #1 D+0 Ilana Roberts
40 Responders Non- Responders
41 Conclusions/Future Directions Combination of T cell therapy and anti-ctla4 leads to establishment of long-lived central memory T-cells. Evidence of epitope spreading was observed in patients with tumor regression/stable disease. Established a highly effective outpatient strategy > 60% disease control in patients with metastatic dz Phase II study -> 30 patients (MD Anderson Cancer Center)
42 Endogenous T Cell Therapy (ETC) Source Peripheral Blood < % TCR repertoire self-selected affinity Unbiased from TIL Accessible Peripheral blood Low morbidity/outpatient Regulatory simplicity Genetic modification Rapid deployment Discovery Implementation Flexibility Time and labor-intensive technically challenging
43 Microbrewery or Beer Factory 43
44 T Cell Therapy Source Enrichment Expansion Peripheral Blood APC + peptide STIM 1 < % > 80 % > 80 % weeks
45 FITC-A <FITC-A> Clinical Grade pmhc-multimer-based Sorting Specimen_001_E2_E02.fcs FSC-A, SSC-A subset cd4 isolation exp3_2537-so2 EB REP INF1.fcs FSC-H, SSC-A su 0.37% % e APC-A <APC-A>
46 T Cell Therapy Source Enrichment Expansion Peripheral Blood APC + peptide STIM 1 < % > 80 % > 80 % weeks
47 T Cell Therapy: Enabling Technologies Turnkey Operation Source Selection Expansion Peripheral Blood APC + peptide STIM 1 +IL-21 MART-1 NY-ESO-1 MAGE-A3 MAGE-A1 PRAME WT-1 Melanoma Lung Head and Neck Hepatocellular GI/ Gastric Survivin
48 Beyond Melanoma Anti-CTLA4 Anti-PD1 Hodi et al, NEJM 2010 Topalian S L et al. JCO 2014 Lawrence et al, Nature. 2013
49 A NY-ESO-1 is expressed in MRCL with high prevalence and homogeneity B C Pollack et al Cancer, 2011 PLOS One 2012
50 % Tetramer Tetramer Tetramer Tetramer NY-ESO-1+ T-cells targeting HLA A*2402/NY-ESO-1 I (Metastatic Breast Cancer) 0.94% 0.92% 3.55% CD8 CD8 CD Anti-CTLA HD-Cytoxan (Day -3) Infusion #1 (Day 0) LD- Cytoxan (Day 31) Infusion #2 (Day 34) A. Ribas J Glaspy C Yee
51 Greg Lizee Identifying new antigens
52
53 Generation of SLC45A2 specific CTLs Schematic steps DC stimulation of CD8 T cells SLA45A2 peptide (R/S) 1 st stimulation 2 nd stimulation Tetramer staining Sorting of tetramer+ CD8 T cells REP Cloning Cloning Tetramer staining CRA CRA CRA REP REP REP SLC45A2 specific CD8 T cells Jungsun Park
54 Generation of SLC45A2 specific CTLs Tetramer staining 2.25% 2.31% 6.21%
55 Mel 888+A2 Specific lysis (%) Specific lysis (%) Specific lysis (%) Specific lysis (%) Specific lysis (%) Specific lysis (%) Specific lysis (%) Specific lysis (%) Generation of SLC45A2 specific CTLs Cytotoxic activity of SLC45A2 specific CTL Mel 2381 Mel 2508 Mel 2400 Mel :1 10:1 Mel E:T 2382 ratio 5:1 2.5: :1 10:1 Mel E:T 2559 ratio 5:1 2.5:1 0 20:1 10:1 Mel E:T 2461 ratio 5:1 2.5:1 0 20:1 10:1 5:1 Mel E:T 2333 ratio SLC45A2-neg SLC45A2-neg SLC45A2-neg : :1 10:1 5:1 2.5:1 0 20:1 10:1 5:1 2.5:1 0 20:1 10:1 5:1 2.5:1 0 20:1 10:1 5:1 2.5:1 E:T ratio E:T ratio E:T ratio E:T ratio Expression of SLC45A2 in melanoma cell lines RT-PCR SLC45A2 GAPDH SLC45A2-specific CTL can effectively kill SLC45A2- expressing melanoma cells
56 Mel 526 A375 Melanocyte 4C Melanocyte 3C Specific lysis (%) Specific lysis (%) SLC45A2 is a tumor-specific differentiation antigen SLC45A2 Mel A375 Melanocyte 3C Melanocyte 80 4C MART-1 (#160) MART-1 Mel 526 A375 Mel 526 A375 Melanocyte 3C Melanocyte 3C Melanocyte 4C Melanocyte 4C :1 20:1 10:1 E:T ratio 5:1 2.5:1 0 40:1 20:1 10:1 E:T ratio 5:1 2.5:1 SLC45A2 MART-1 Gp100 Tyrosinase GAPDH
57 GBM Antigen-specific T cell Generation Project in collaboration with Immatics
58 Antigen-specific T cell generation Leukapheresis Dendritic Cells Pulsed with antigen Pulsed with antigen CD25 Depletion Stim #1 Stim #2 Goal is to generate autologous tumor antigen-specific cytotoxic T cells from normal donor PBMCs Stim QC Bulk Well FACSAria Fusion Sort Bulk Well Sort1 REP1 REP QC (Stain, CRA) Testing a wide variety of antigens, currently focusing on GBM-specific 19 GBM antigen peptides currently tested 6 currently in Stim 1 Freeze
59 Tetramer - PE Staining for tetramer positive T-cells after 2 nd stimulation with example antigen Stimulations performed in 48- well plates These bulk wells are pooled and then sorted for REP (next slide) CD8 - APC
60 Tetramer - PE Tetramer-guided enrichment of GBM-specific CTL population Pre-REP Post-REP CD8 - APC Sort stain (bulk well pool) About 8x10 3 (CD8 + Tet + ) T cells sorted 94x10 6 expanded (12,000-fold expansion)
61 Conclusions Non-melanoma solid tumor malignancies can be targeted by ETC MS/exome/RNA seq analysis yield new epitopes that can elicit peptide-specific T cells Such T cells are capable of recognizing tumor cells presenting endogenous antigen Peptide epitopes identified by this approach are immunogenic and represent potential tumor rejection antigens
62 The Beer Beer Margarita paradigm Cytokines Chemokines The Margarita CD8 CD4 T cm T eff T fh Th 1-50 NK NKT Genetic Modification -safety -knockdown -conditional expression CTLA4 PD1/PD-L1 GITR OX40 CD40 CD137 Vaccine Therapy Oncolytic Virotherapy Radiation Therapy Targeted Therapy Chemotherapy
63 Transferrable Biomarker IL-2 CD8+ T cell TNF-a TCR IFN-g CD127 CD28 Post-infusion Immunomodulation Antigen-specific T cells Pre-infusion Tetramer+ T cells From PBMC Pre-Immunomodx Analysis of antigen-specific T cells Pre-vs Post-immunomodulatory therapy Tetramer+ T cells From PBMC Post-Immunomodx - In vivo frequency - In vivo persistence - In vivo trafficking - In vivo function - Differentiation/phenotype - Transcirptional signature
64
65 Aude Chapuis Seth Pollack Yongqing Li Ivy Lai Erik Farrar Junmei Wang Eric Mortenson Nicole Cecchini This Research was supported by: CPRIT Stand Up to Cancer-AACR/CRI Cancer Research Institute Burroughs Wellcome Fund Damon Runyon Sister Institutions Network Funding (GAP)
Adoptive Cellular Therapy SITC Primer October 2012
Adoptive Cellular Therapy SITC Primer October 2012 Cassian Yee MD Member Fred Hutchinson Cancer Research Center Program in Immunology Clinical Research Division Professor University of Washington Division
More informationAdoptive cell therapy using genetically modified antigen-presenting cells
Adoptive cell therapy using genetically modified antigen-presenting cells Naoto Hirano Ontario Cancer Institute Princess Margaret Cancer Centre University of Toronto UofT-USP Oncology Conference November
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationDEVELOPMENT OF CELLULAR IMMUNOLOGY
DEVELOPMENT OF CELLULAR IMMUNOLOGY 1880 s: Antibodies described (dominated studies of immunology until 1960 s) 1958: Journal of Immunology (137 papers) lymphocyte not listed in index Two papers on transfer
More informationTumors arise from accumulated genetic mutations. Tumor Immunology (Cancer)
Tumor Immunology (Cancer) Tumors arise from accumulated genetic mutations Robert Beatty MCB150 Mutations Usually have >6 mutations in both activation/growth factors and tumor suppressor genes. Types of
More informationSupporting Information
Supporting Information Chapuis et al. 10.1073/pnas.1113748109 SI Methods Selection of Patients, Targets, Isolation, and Expansion of Melanoma- Specific CTL Clones. Patients were HLA-typed, and their tumors
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationBasic Principles of Tumor Immunotherapy. Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA
Basic Principles of Tumor Immunotherapy Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA Disclosures Consulting Fees: Biodesix, Novartis Pharmaceuticals Other: Boehringer
More informationCancer immunity and immunotherapy. General principles
1 Cancer immunity and immunotherapy Abul K. Abbas UCSF General principles 2 The immune system recognizes and reacts against cancers The immune response against tumors is often dominated by regulation or
More informationAdvances in Adoptive Cellular Therapy of Cancer. Melanoma Bridge Meeting December 5, 2014
Advances in Adoptive Cellular Therapy of Cancer Melanoma Bridge Meeting December 5, 2014 David Stroncek, MD Chief, Cell Processing Section, DTM, CC, NIH Bethesda, Maryland, USA Disclosures None Focus
More informationA Multifaceted Immunomonitoring to Identify Predictive Biomarkers for the Clinical Outcome of Immunotherapy-Treated Melanoma Patients
A Multifaceted Immunomonitoring to Identify Predictive Biomarkers for the Clinical Outcome of Immunotherapy-Treated Melanoma Patients Immunotherapy Biomarkers: Overcoming the Barriers NIH, Bethesda, April
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationCancer Immunotherapy: Active Immunization Approaches
Cancer Immunotherapy: Active Immunization Approaches Willem W. Overwijk, PhD Department of Melanoma Medical Oncology MD Anderson Cancer Center Houston, TX, USA Disclosures No relevant financial relationships
More informationPriming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics
Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer
More informationNIH Public Access Author Manuscript Science. Author manuscript; available in PMC 2008 March 12.
NIH Public Access Author Manuscript Published in final edited form as: Science. 2006 October 6; 314(5796): 126 129. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes Richard
More informationThe Immune System. Innate. Adaptive. - skin, mucosal barriers - complement - neutrophils, NK cells, mast cells, basophils, eosinophils
Objectives - explain the rationale behind cellular adoptive immunotherapy - describe methods of improving cellular adoptive immunotherapy - identify mechanisms of tumor escape from cellular adoptive immunotherapy
More informationEndogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade
Endogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade Jedd Wolchok Ludwig Center for Cancer Immunotherapy Memorial Sloan-Kettering Cancer Center MEMORIAL SLOAN- KETTERING
More informationDeterminants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco
Determinants of Immunogenicity and Tolerance Abul K. Abbas, MD Department of Pathology University of California San Francisco EIP Symposium Feb 2016 Why do some people respond to therapeutic proteins?
More informationExploring Therapeutic Combinations with anti-ctla-4 Antibody
Exploring Therapeutic Combinations with anti-ctla-4 Antibody Padmanee Sharma, MD, PhD Associate Professor GU Medical Oncology and Immunology M. D. Anderson Cancer Center isbtc Hot Topic Symposium October
More information08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells
Tumor Immunotherapy Autologous virus Inactivation Inactivated virus Lymphopheresis Culture? Monocyte s Dendritic cells Immunization Autologous vaccine Development of Tumor Vaccines Types of Tumor Vaccines
More informationImmunotherapy for the Treatment of Cancer
Immunotherapy for the Treatment of Cancer Jason Muhitch, PhD Assistant Professor Department of Urology Department of Immunology Roswell Park Comprehensive Cancer Center Oncology for Scientists March 15,
More information2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical
More informationRadiation Therapy as an Immunomodulator
Radiation Therapy as an Immunomodulator Yvonne Mowery, MD, PhD February 20, 2017 Tumor/Immune System Balance Kalbasi, JCI 2013 UNC-Duke-NC State-Wake Forest Spring 2017 2 RT Can Shift Balance Toward Elimination
More informationInnovation in Prevention, Early Detection & Diagnosis of Colorectal Cancer Heidelberg Workshop Session VI, Oncology Pipeline June 6, 2014
Innovation in Prevention, Early Detection & Diagnosis of Colorectal Cancer Heidelberg Workshop Session VI, Oncology Pipeline June 6, 2014 Bernd Mueller MSD Sharp & Dohme, Germany Normal Immune Surveillance:
More informationNKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity
NKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity Peiwen Kuo Scientist, Research Biology Nektar Therapeutics August 31 st, 2018 Emerging
More information- Defined as approaches that enhance, suppress or modify the immune system to treat or cure diseases.
암의면역치료 권병세 Immunotheraphy - Defined as approaches that enhance, suppress or modify the immune system to treat or cure diseases. - Applied for the treatment of cancer, autoimmune diseases, transplant rejection,
More informationTumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School
Tumor Immunity and Immunotherapy Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Lecture Outline Evidence for tumor immunity Types of tumor antigens Generation of anti-tumor
More informationSynergistic combinations of targeted immunotherapy to combat cancer
Synergistic combinations of targeted immunotherapy to combat cancer Myung Ah Lee, M.D., Ph. D Division of Medical Oncology, Hepato-biliary pancreatic cancer center Seoul St. Mary s hospital, The Catholic
More informationTITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer
AD Award Number: W8-XWH-5-- TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer PRINCIPAL INVESTIGATOR: Mathias Oelke, Ph.D. CONTRACTING ORGANIZATION: Johns Hopkins
More informationNew insights into CD8+ T cell function and regulation. Pam Ohashi Princess Margaret Cancer Centre
New insights into CD8+ T cell function and regulation Pam Ohashi Princess Margaret Cancer Centre New insights into CD8+ T cell function and regulation Pam Ohashi Princess Margaret Cancer Centre No Disclosures
More informationCancer Immunotherapy. What is it? Immunotherapy Can Work! 4/15/09. Can the immune system be harnessed to fight cancer? T CD4 T CD28.
Cancer Immunotherapy CANCER BIOLOGY April 15, 2009 Can the immune system be harnessed to fight cancer? Can the immune system see cancer? What is the best way to turn on the immune system to fight cancer?
More informationCONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205
AD Award Number: DAMD7---7 TITLE: Development of Artificial Antigen Presenting Cells for Prostate Cancer Immunotherapy PRINCIPAL INVESTIGATOR: Jonathan P. Schneck, M.D., Ph.D. Mathias Oelke, Ph.D. CONTRACTING
More informationIs Immune Therapy the Holy Grail in Metastatic Kidney Cancer?
Is Immune Therapy the Holy Grail in Metastatic Kidney Cancer? New Frontiers in Urologic Oncology 8-2016 Mayer Fishman, MD PhD Member, Moffitt Cancer Center Department of Genitourinary Oncology Professor,
More informationTherapeutic efficacy of MUC1- specific CTL and CD137 costimulation. mammary cancer model. Pinku Mukherjee & Sandra Gendler
Therapeutic efficacy of MUC1- specific CTL and CD137 costimulation in a spontaneous mammary cancer model Pinku Mukherjee & Sandra Gendler Goal of Immunotherapy Boosting the low level anti-tumor immune
More informationInterleukin-2 Single Agent and Combinations
Interleukin-2 Single Agent and Combinations Michael K Wong MD PhD Norris Cancer Center University of Southern California mike.wong@med.usc.edu Disclosures Advisory Board Attendance Merck Bristol Myers
More informationAdoptive Cell Therapy: Treating Cancer
Adoptive Cell Therapy: Treating Cancer with Genetically Engineered T Cells Steven A. Feldman, Ph.D. Surgery Branch National Cancer Institute NCT Conference Heidelberg, Germany September 24, 2013 Three
More informationAdministration of Tumor-Specific Cytotoxic T Lymphocytes Engineered to Resist TGF-ß to Patients with EBV-Associated Lymphomas
Administration of Tumor-Specific Cytotoxic T Lymphocytes Engineered to Resist TGF-ß to Patients with EBV-Associated Lymphomas CM. Bollard, G Dotti, S Gottschalk, E Liu, A Sheehan, M Mims, H Liu, AP. Gee,
More informationCytokines: Interferons, Interleukins and Beyond. Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center
Cytokines: Interferons, Interleukins and Beyond Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center Disclosures Advisory Boards: Bristol-Myers Squibb,Amgen, Novartis, Alkermes, Infinity,
More informationThe next steps for effective cancer immunotherapy and viral vaccines. Peter Selby FACP(UK)
The next steps for effective cancer immunotherapy and viral vaccines Peter Selby FACP(UK) Richard Alan Steve Sasha Matt Nav Vile Melcher Griffin Zougman Bentham Vasudev Adel Nick Gemma Liz Samson Hornigold
More informationSupplemental materials
Supplemental materials 1 Supplemental Fig. 1 Immunogram This immunogram summarizes patient clinical data and immune parameters at corresponding time points for Patient IMF-32. The top panel illustrates
More informationAntigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS
1 Antigen Presentation and T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28 family
More informationFocus on Immunotherapy as a Targeted Therapy. Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct
Focus on Immunotherapy as a Targeted Therapy Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct 18 2018 Disclosures I have nothing to disclose that is relevant to this presentation. Immunology @ Deeley
More informationTITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer
AD Award Number: W8XWH-5-- TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer PRINCIPAL INVESTIGATOR: Mathias Oelke Ph.D. CONTRACTING ORGANIZATION: Johns Hopkins
More informationNKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies
NKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies Saul Kivimäe Senior Scientist, Research Biology Nektar Therapeutics NK Cell-Based Cancer Immunotherapy, September 26-27,
More informationDeveloping Novel Immunotherapeutic Cancer Treatments for Clinical Use
Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use Oncology for Scientists March 8 th, 2016 Jason Muhitch, PhD Assistant Professor Department of Urology Email: jason.muhitch@roswellpark.org
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationTITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer
AD Award Number: W8-XWH-5-- TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer PRINCIPAL INVESTIGATOR: Mathias Oelke,. CONTRACTING ORGANIZATION: Johns Hopkins
More informationCancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
More informationDarwinian selection and Newtonian physics wrapped up in systems biology
Darwinian selection and Newtonian physics wrapped up in systems biology Concept published in 1957* by Macfarland Burnet (1960 Nobel Laureate for the theory of induced immune tolerance, leading to solid
More information10/3/2016. Immunotherapy of human cancer can be highly effective: TIL therapy. What T cells See on Human Cancer. Anti-PD-1. Anti-PD-1 and anti-ctla-4
Immunotherapy of human cancer can be highly effective: TIL therapy Tumor-infiltrating lymphocytes (TIL) are grown from melanoma tumors Rapid Expansion Infusion of TIL + IL-2 What T cells See on Human Cancer
More informationMHC Tetramers and Monomers for Immuno-Oncology and Autoimmunity Drug Discovery
MHC Tetramers and Monomers for Immuno-Oncology and Autoimmunity Drug Discovery Your Partner in Drug Discovery and Research MHC Tetramer Background T-Cell Receptors recognize and bind to complexes composed
More informationReleasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies
Releasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies Jason Muhitch, PhD MIR 509 October 1 st, 2014 Email: jason.muhitch@roswellpark.org 0 Holy Grail of Tumor Immunity Exquisite
More informationDisclosure Information. Mary L. Disis
Disclosure Information Mary L. Disis I have the following financial relationships to disclose: Consultant for: VentiRx, Celgene, Emergent, EMD Serono Speaker s Bureau for: N/A Grant/Research support from:
More informationGeneral Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center
General Overview of Immunology Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center Objectives Describe differences between innate and adaptive immune responses
More informationVISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses. Li Wang. Dartmouth Medical School
VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses Li Wang Dartmouth Medical School The B7 Immunoglobulin Super-Family immune regulators APC T cell Co-stimulatory:
More informationUnderstanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D.
Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies Michael A. Curran, Ph.D. MD Anderson Cancer Center Department of Immunology Disclosures I have research
More informationSupplementary Figure 1. Example of gating strategy
Supplementary Figure 1. Example of gating strategy Legend Supplementary Figure 1: First, gating is performed to include only single cells (singlets) (A) and CD3+ cells (B). After gating on the lymphocyte
More informationImmunotherapy: The Newest Treatment Route
Immunotherapy: The Newest Treatment Route IWMF Patient Forum, Phoenix, AZ Madhav Dhodapkar, MD Professor of Medicine and Immunobiology Chief, Section of Hematology Yale University or the Oldest William
More informationImmunotherapy on the Horizon: Adoptive Cell Therapy
Immunotherapy on the Horizon: Adoptive Cell Therapy Joseph I. Clark, MD, FACP Professor of Medicine Loyola University Chicago Stritch School of Medicine Maywood, IL June 23, 2016 Conflicts of Interest
More information2/19/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
F141: Advanced Melanoma: Mechanisms of Immune Therapies beyond Checkpoint blockade Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los
More informationCell Therapies. John HaanenMD PhD
Cell Therapies John HaanenMD PhD My disclosures I have provided consultation, attended advisory boards, and/or provided lectures for: Pfizer, Bayer, MSD, BMS, IPSEN, Novartis, Roche/Genentech, Astra Zeneca/MedImmune,
More informationDefective STAT1 activation associated with impaired IFN-g production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2
Defective STAT1 activation associated with impaired IFN-g production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2 SUPPLEMENTARY FIGURES AND TABLES Supplementary Figure S1:
More informationExploring Immunotherapies: Beyond Checkpoint Inhibitors
Exploring Immunotherapies: Beyond Checkpoint Inhibitors Authored by: Jennifer Dolan Fox, PhD VirtualScopics (Now part of BioTelemetry Research) jennifer_fox@virtualscopics.com +1 585 249 6231 Introduction
More informationThe Good, the Bad and the Ugly: Clinical trials which assess vaccine characteristics. ISBT Meeting, San Francisco, CA November 4-8, 2004
The Good, the Bad and the Ugly: Clinical trials which assess vaccine characteristics ISBT Meeting, San Francisco, CA November 4-8, 2004 Ideal cancer vaccine trial 1. An informative immune assay 2. Ability
More informationT Cell Activation, Costimulation and Regulation
1 T Cell Activation, Costimulation and Regulation Abul K. Abbas, MD University of California San Francisco 2 Lecture outline T cell antigen recognition and activation Costimulation, the B7:CD28 family
More informationDendritic Cell-Based Immunotherapy Vaccines for Melanoma and Hepatocellular Cancer
Dendritic Cell-Based Immunotherapy Vaccines for Melanoma and Hepatocellular Cancer Lisa H. Butterfield, Ph.D. Assistant Professor of Medicine, Surgery and Immunology University of Pittsburgh Cancer Institute
More informationMolecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy
Molecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader,
More informationEmerging Concepts of Cancer Immunotherapy
Emerging Concepts of Cancer Immunotherapy Jeffrey Schlom, Ph.D. Laboratory of Tumor Immunology and Biology (LTIB) Center for Cancer Research National Cancer Institute, NIH Immune Cell Infiltrate in Primary
More informationEngineered Immune Cells for Cancer Therapy : Current Status and Prospects
When Engineering Meets Immunology Engineered Immune Cells for Cancer Therapy : Current Status and Prospects Yong Taik Lim, Ph.D. Nanomedical Systems Laboratory (http://www.nanomedicalsystems.org) SKKU
More informationOverview 4/11/2013. Cell Kinetics in Adoptive Cell Therapy. April 11, 2013
Cell Kinetics in Adoptive Cell Therapy April 11, 2013 David Stroncek, MD Chief, Cellular Processing Section DTM, CC, NIH Cellular Therapies Cell suspensions used for therapeutic purposes Examples Red Cells
More informationImmuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning
Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Yi-Hsiang Hsu, MD, SCD Sep 16, 2017 yihsianghsu@hsl.harvard.edu Director & Associate
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER. Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia
IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Distinguishing self from non-self T cells trained in the thymus as
More informationCTLA4 Blockade in Melanoma Treatment. Antoni Ribas, M.D. Associate Professor of Medicine and Surgery University of California Los Angeles.
CTLA Blockade in Melanoma Treatment Antoni Ribas, M.D. Associate Professor of Medicine and Surgery University of California Los Angeles. CTLA Negatively Modulates T-Cell Activation MHC Antigen TCR Dendritic
More informationOverview 3/31/2016. Cell Kinetics in Adoptive Cell Therapy. March 31, 2016
Cell Kinetics in Adoptive Cell Therapy March 31, 2016 David Stroncek, MD Chief, Cellular Processing Section DTM, CC, NIH Cellular Therapies Cell suspensions used for therapeutic purposes Examples Red Cells
More informationCell Kinetics in Adoptive Cell Therapy. March 31, 2016
Cell Kinetics in Adoptive Cell Therapy March 31, 2016 David Stroncek, MD Chief, Cellular Processing Section DTM, CC, NIH 1 Cellular Therapies Cell suspensions used for therapeutic purposes Examples Red
More informationTumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant
Tumor Immunology Wirsma Arif Harahap Surgical Oncology Consultant 1) Immune responses that develop to cancer cells 2) Escape of cancer cells 3) Therapies: clinical and experimental Cancer cells can be
More informationLAMPvax DNA Vaccines as Immunotherapy for Cancer - Three Case Studies
LAMPvax DNA Vaccines as Immunotherapy for Cancer - Three Case Studies Cancer immunotherapy has emerged as a clinically validated tool for fighting certain kinds of cancers. These therapeutic cancer vaccines
More informationRestoring Immune Function of Tumor-Specific CD4 + T Cells during Recurrence of Melanoma
Restoring Immune Function of Tumor-Specific CD4 + T Cells during Recurrence of Melanoma Goding SR et al. J Immunol 2013; 190:4899-4909 C. Nikolowsky Christian Doppler Laboratory for Cardiac and Thoracic
More informationACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT
ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes
More informationPotential cross reactions between HIV 1 specific T cells and the microbiome. Andrew McMichael Suzanne Campion
Potential cross reactions between HIV 1 specific T cells and the microbiome Andrew McMichael Suzanne Campion Role of the Microbiome? T cell (and B cell) immune responses to HIV and Vaccines are influenced
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More informationFocus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human melanoma
Cancer Immun 1424-9634Academy of Cancer Immunology Cancer Immunity (2 April 2009) Vol. 9, p. 3 Copyright 2009 by Martin C. Mihm Jr. 090101 Review Focus on TILs: Prognostic significance of tumor infiltrating
More informationCancer immunotherapy with oncolytic viruses: more than just lysis
Cancer immunotherapy with oncolytic viruses: more than just lysis Dmitriy Zamarin MD PhD Assistant Attending, Immune Therapeutics Center Memorial Sloan-Kettering Cancer Center New York, NY BCAN Think Tank
More informationRadiation Therapy and Immunotherapy: New Frontiers
Radiation Therapy and Immunotherapy: New Frontiers Nevada Oncology Society Fall Meeting November 16 th, 2017 Anshu K. Jain, MD Radiation Oncologist, Ashland Bellefonte Cancer Center Assistant Clinical
More informationSupplementary Data. Treg phenotype
Supplementary Data Additional Experiment An additional experiment was performed using cryopreserved peripheral blood mononuclear cells (PBMC) derived from five renal cell carcinoma (RCC) patients [see
More informationEmerging Targets in Immunotherapy
Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy
More informationImmuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning
Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Yi-Hsiang Hsu, MD, SCD Sep 16, 2017 yihsianghsu@hsl.harvard.edu HSL GeneticEpi Center,
More informationChapter 7 Conclusions
VII-1 Chapter 7 Conclusions VII-2 The development of cell-based therapies ranging from well-established practices such as bone marrow transplant to next-generation strategies such as adoptive T-cell therapy
More informationDissecting therapy-induced T-cell responses in melanoma
Dissecting therapy-induced T-cell responses in melanoma Tumor-infiltrating lymphocyte (TIL) therapy of melanoma TIL are grown from melanoma tumors Rapid Expansion Infusion of TIL + IL-2 Patient pretreated
More informationEffector T Cells and
1 Effector T Cells and Cytokines Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School 2 Lecture outline Cytokines Subsets of CD4+ T cells: definitions, functions, development New
More informationCancer Progress. The State of Play in Immuno-Oncology
Cancer Progress The State of Play in Immuno-Oncology Axel Hoos, MD, PhD VP, Oncology R&D, Glaxo Smith Kline Co-Director, Cancer Immunotherapy Consortium Key Drivers in Immuno-Oncology Science Methods Combinations
More informationEnhancing the Clinical Activity of HER2/neu Specific T Cells. William Gwin, MD Internal Medicine, Resident University of Washington
Enhancing the Clinical Activity of HER2/neu Specific T Cells William Gwin, MD Internal Medicine, Resident University of Washington Immunotherapy and Cancer Cancer vaccines were originally used in melanoma
More informationThe PD-1 pathway of T cell exhaustion
The PD-1 pathway of T cell exhaustion SAMO 18.3.2016 Overview T cell exhaustion Biology of PD-1 Mechanism Ligands expressed on tumor cell and on non-tumor cells other receptor pairs Biomarkers for apd-1/pd-l1
More informationCurrent practice, needs and future directions in immuno-oncology research testing
Current practice, needs and future directions in immuno-oncology research testing Jose Carlos Machado IPATIMUP - Porto, Portugal ESMO 2017- THERMO FISHER SCIENTIFIC SYMPOSIUM Immune Therapies are Revolutionizing
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationSupplemental Table I.
Supplemental Table I Male / Mean ± SEM n Mean ± SEM n Body weight, g 29.2±0.4 17 29.7±0.5 17 Total cholesterol, mg/dl 534.0±30.8 17 561.6±26.1 17 HDL-cholesterol, mg/dl 9.6±0.8 17 10.1±0.7 17 Triglycerides,
More informationCancer Vaccines. Patrick Ott. Melanoma Disease Center Center for Immuno-Oncology Dana Farber Cancer Institute Harvard Medical School
Cancer Vaccines Patrick Ott Melanoma Disease Center Center for Immuno-Oncology Dana Farber Cancer Institute Harvard Medical School Patrick A. Ott, MD, PhD The following relationships exist related to this
More informationPersonalized medicine - cancer immunotherapy
Personalized medicine - cancer immunotherapy Özcan Met, PhD Senior Staff Scientist, Cell Therapy Director Center for Cancer Immune Therapy Department of Hematology Department of Oncology University Hospital
More information